Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.64 |
| ▸ | TNNI3K | Q59H18 | 10/20 | 0.64 |
| ▸ | BRAF | P15056 | 10/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766143 | 0.91 | KDR (0.61) | KDRMAPK14TNNI3KBRAFMAP3K7 | |
| SCHEMBL4769716 | 0.90 | MAP3K7 (0.55) | KDRMAPK14TNNI3KBRAFMAP3K7 | |
| SCHEMBL4766055 | 0.89 | MAP3K7 (0.69) | KDRMAPK14TNNI3KBRAFMAP3K7 | |
| SCHEMBL4769351 | 0.86 | KDR (0.64) | KDRMAPK14TNNI3KBRAFMAP3K7 | |
| SCHEMBL13528824 | 0.83 | SRC (0.60) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL4939906 | 0.80 | KDR (0.71) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL4763219 | 0.80 | KDR (0.69) | KDRMAPK14TNNI3KBRAFMAP3K7 | |
| SCHEMBL4936701 | 0.80 | KDR (0.73) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL4932660 | 0.79 | KDR (0.66) | KDRMAPK14TNNI3KBRAFMAP3K7 | |
| SCHEMBL4762311 | 0.79 | KDR (0.67) | KDRMAPK14TNNI3KBRAFMAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511730-B1 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-12-10 | — | — | EP | claimed |
| EP-1511730-B1 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-12-10 | — | — | EP | disclosed |